PUMA BIOTECHNOLOGY, INC.
PUMA BIOTECHNOLOGY, INC. (PBYI): 3 pipeline candidates · 2 upcoming catalysts · ~9 mo cash runway · 21 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
8.7 months
D/E 0.50 · 0% dilution
Lead: Approved
3 candidates
2 upcoming, next in ~104d
0 buys · 6 sells (180d)
A transparent, data-derived signal for PUMA BIOTECHNOLOGY, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$358.8M
Cash
$36.2M
Quarterly Burn
$38.2M
Runway
8.7 mo
Revenue
$44.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| alisertib | Phase 2 |
| nerlynx | Approved |
| rpesc-rpe-4w | Phase 1/Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
157
Total value held
$233.2M
| Holder | Shares | Value |
|---|---|---|
| acorn capital advisors, llc | 4,131,299 | $26.4M |
| vanguard capital management llc | 3,635,362 | $23.2M |
| blackrock, inc. | 3,598,952 | $23.0M |
| renaissance technologies llc | 1,942,413 | $12.4M |
| american century companies inc | 1,916,346 | $12.2M |
| vanguard portfolio management llc | 1,734,649 | $11.1M |
| millennium management llc | 1,477,519 | $9.4M |
| dimensional fund advisors lp | 1,436,106 | $9.2M |
| o'shaughnessy asset management, llc | 1,138,169 | $7.3M |
| geode capital management, llc | 1,017,342 | $6.5M |
Showing top 10 of 157 institutional holders of PUMA BIOTECHNOLOGY, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PUMA BIOTECHNOLOGY, INC.'s pipeline?
PUMA BIOTECHNOLOGY, INC. (PBYI) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PUMA BIOTECHNOLOGY, INC.'s lead drug candidate?
PUMA BIOTECHNOLOGY, INC.'s most advanced tracked candidate is alisertib (Phase 2) for Small Cell Lung Cancer ( SCLC ); Small Cell Lung Cancer.
What is PUMA BIOTECHNOLOGY, INC.'s next catalyst?
PUMA BIOTECHNOLOGY, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer" — expected September 30, 2026.
What is PUMA BIOTECHNOLOGY, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PUMA BIOTECHNOLOGY, INC. has approximately 8.7 months of cash runway.
What is PUMA BIOTECHNOLOGY, INC.'s market capitalization?
PUMA BIOTECHNOLOGY, INC.'s market capitalization is approximately $358.8M.
Get the full picture on PUMA BIOTECHNOLOGY, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.